Vizsgálati helyszín
North Shore Hospital
Auckland, 0622, Új-ZélandMég nincs intézményhez kötve
- 19futó vizsgálat
- 4lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 23 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis14 vizsgálat
- 2. fázis3 vizsgálat
- 1/2. fázis1 vizsgálat
- 4. fázis1 vizsgálat
- Állapot
- Toboroz10 vizsgálat
- Fut, nem toboroz8 vizsgálat
- Leállították3 vizsgálat
- Lezárult1 vizsgálat
- Még nem toboroz1 vizsgálat
- Fő szponzor
- BeOne Medicines6 vizsgálat
- Bristol-Myers Squibb2 vizsgálat
- Janssen Research & Development, LLC2 vizsgálat
- Pfizer2 vizsgálat
- Smith & Nephew, Inc.2 vizsgálat
- és még 9
Futó vizsgálatok
Toboroz
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
NCT07277231· 3. fázis· BeOne Medicines· Forrás
Contact: Study Director
Toboroz
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187· 3. fázis· BeOne Medicines· Forrás
Contact: Study Director
Toboroz
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
NCT06929273· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: Sylvester Miles, Site 0086
Toboroz
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
NCT06951698· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: Sylvester Miles, Site 0055
Toboroz
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872· 3. fázis· BeOne Medicines· Forrás
Contact: Study Director
Toboroz
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
NCT06742996· 3. fázis· BeOne Medicines· Forrás
Contact: Study Director
Fut, nem toboroz
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483· 3. fázis· Takeda· Forrás
Toboroz
Depth of Anesthesia on Postoperative Delirium and Cognitive After Surgery
NCT06268080· Auckland City Hospital· Forrás
Contact: Davina J McAllister, DipNursing
Fut, nem toboroz
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06073821· 3. fázis· BeOne Medicines· Forrás
Fut, nem toboroz
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
NCT05623020· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
Study to Evaluate the Safety and Effectiveness of the REAL INTELLIGENCE™ CORI™ in Total Knee Arthroplasty (TKA) Procedure
NCT04848896· Smith & Nephew, Inc.· Forrás
Toboroz
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
NCT05020236· 3. fázis· Pfizer· Forrás
Toboroz
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04920617· 2. fázis· ImmunoVaccine Technologies, Inc. (IMV Inc.)· Forrás
Contact: Sophie Leitch, MD
Toboroz
A Study of BGB-11417 in Participants With Myeloid Malignancies
NCT04771130· 1/2. fázis· BeOne Medicines· Forrás
Contact: Study Director
Toboroz
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
NCT03860883· Melanoma and Skin Cancer Trials Limited· Forrás
Contact: Dr Richard Martin
Fut, nem toboroz
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
NCT03229200· 4. fázis· Pharmacyclics Switzerland GmbH· Forrás
Toboroz
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
NCT02735707· 3. fázis· UMC Utrecht· Forrás
Contact: Robert Everitt, MD
Fut, nem toboroz
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT02227251· 2. fázis· Karyopharm Therapeutics Inc· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek